Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03846479
Other study ID # GCO 18-1684
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 25, 2019
Est. completion date May 11, 2022

Study information

Verified date February 2023
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can lead to serious complications. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk GVHD). This study will test whether patients with low risk GVHD can be successfully treated without steroids. Patients who participate with this study will be treated with itacitinib instead of steroids. Itacitinib is an experimental drug with an excellent safety record and appears to have activity as a GVHD treatment.


Description:

Patients with newly diagnosed low risk acute GVHD defined as Minnesota standard risk based on symptoms and Ann Arbor 1 GVHD based on biomarkers were eligible if they met all other eligible criteria (see eligibility criteria below). Enrolled patients were required to start treatment within 4 days of confirmation of Ann Arbor 1 status. Treatment consisted of itacitinib 200 mg daily for 28 days. Patients with a clinical response on day 28 were eligible for a second 28 day cycle of itacitinib 200 mg daily. Missed doses could be made up by extending the treatment duration for up to 2 additional weeks. Medications given for GVHD prophylaxis and topical treatments for GVHD were allowed. Supportive care was provided according to institutional standards. Itacitinib was permanently discontinued after any of the following: administration of 56 doses of itacitinib or initiation of systemic corticosteroids or any other systemic treatment for GVHD or patient withdrawal from the study or general or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator OR ten weeks elapsed since the first dose of itacitinib.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date May 11, 2022
Est. primary completion date May 7, 2021
Accepts healthy volunteers No
Gender All
Age group 12 Years to 75 Years
Eligibility Inclusion Criteria: - Newly diagnosed GVHD that meets criteria for Minnesota standard risk - Ann Arbor 1 GVHD by biomarkers - GVHD not previously treated systemically (topical therapies and non-absorbed steroids are allowed) - Any donor type, HLA-match, conditioning regimen is acceptable - Age 12 - 75 years (children <18 years must also weigh 50 kg or more) - Patients must be engrafted post-transplant (ANC >500/µL and platelet count >20,000). Use of growth factor supplementation to maintain neutrophil count is allowed. - Direct bilirubin must be <2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment. - ALT/SGPT and AST/SGOT must be <5x the upper limit of the normal range within 3 days prior to enrollment. - Signed and dated written informed consent obtained from patient or legal representative. Exclusion Criteria: - Patients currently being treated with any JAK inhibitor including ruxolitinib - Relapsed, progressing, or persistent malignancy requiring withdrawal of systemic immune suppression - Patients with uncontrolled infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis) - Severe organ dysfunction including requirement for dialysis, mechanical ventilation or oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment. - Creatinine clearance or estimated glomerular filtration rate <30 ml/min as calculated by institutional practice (e.g., Cockcroft-Gault equation, CKD-EPI equation, etc) - A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment - Patients receiving corticosteroids >10 mg/day prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD except for adrenal insufficiency or premedication for transfusions/IV meds - Patients who are pregnant - Patients receiving investigational agents within 30 days of enrollment. However, the Principal Investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of itacitinib - History of allergic reaction to itacitinib or any JAK inhibitor

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Itacitinib
for up to 56 days

Locations

Country Name City State
United States Children's Healthcare of Atlanta Atlanta Georgia
United States Emory University Atlanta Georgia
United States Massachusetts General Hospital Boston Massachusetts
United States Ohio State University Columbus Ohio
United States City of Hope Comprehensive Cancer Center Duarte California
United States University of Kansas Cancer Center Fairway Kansas
United States MD Anderson Cancer Center Houston Texas
United States Children's Hospital of Los Angeles Los Angeles California
United States Vanderbilt University Nashville Tennessee
United States The Mount Sinai Hospital New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
John Levine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Who Achieve CR or PR by Day 28 of Treatment Number of patients who achieve CR or PR by day 28 of treatment with itacitinib without the addition of any other systemic GVHD treatment including steroids.
Complete Response (CR): All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy.
Partial Response (PR): An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy.
Day 28
Primary Number of Participants Who Developed Steroid Refractory GVHD Number of participants who developed steroid refractory GVHD within 28 days of starting steroids. Steroid-refractory GVHD (defined as GVHD that worsens (increase by one or more grade) after 3 days, or fails to respond to treatment within 7 days (for GVHD grade III) or 14 days (for GVHD grade II) or 2nd line therapy beyond systemic steroid treatment is begun within 28 days of starting steroids. Day 28
Secondary Number of Participants With Serious Infectious Number of participants who developed serious infections by day 90. Serious infectious complications is defined as any viral and bacterial infections requiring treatment and proven fungal infections. Day 90
Secondary Number of Participants Alive at 6 Months and 1 Year Number of overall survival (OS), defined as the duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death. 6 months and 1 year
Secondary Number of Participants With Non-relapse Mortality (NRM) Number of participants with non-relapse mortality (NRM) at 6 months and 1 year 6 months and 1 year
Secondary Number of Participants Who Relapsed Number of participants who relapsed by 6 months and by 1 year 6 months and 1 year
Secondary Number of Participants Who Developed Chronic GVHD Number of participants who developed chronic GVHD requiring systemic treatment at 1 year 1 year
Secondary Cumulative Steroid Dose Cumulative steroid dose (over 4 weeks) in patients who receive steroids as second line therapy Day 28
See also
  Status Clinical Trial Phase
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Terminated NCT01940796 - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) Phase 1
Not yet recruiting NCT05544448 - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Not yet recruiting NCT06075225 - MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Phase 2
Not yet recruiting NCT06000982 - Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis Phase 3
Active, not recruiting NCT03680092 - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06083129 - Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Phase 3
Not yet recruiting NCT05094765 - Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD Early Phase 1
Active, not recruiting NCT05415410 - Proof-of-concept Trial of Apraglutide in GVHD Phase 2
Completed NCT02441075 - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 N/A
Completed NCT02588339 - Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Phase 2
Not yet recruiting NCT06334367 - Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT Phase 2
Completed NCT02891603 - A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Phase 1/Phase 2
Completed NCT02712762 - Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
Completed NCT03945591 - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Not yet recruiting NCT06411184 - Safety and Efficacy of Treg Cell in the Treatment of GVHD Phase 1/Phase 2
Terminated NCT02338232 - Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT02156479 - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients